Predictivity of fatty liver index for non-alcoholic fatty liver disease in lean females with polycystic ovary syndrome
April 2022
in “African Health Sciences”
TLDR The Fatty Liver Index (FLI) may not be enough to rule out non-alcoholic fatty liver disease in lean women with polycystic ovary syndrome.
The study conducted from January 2014 to January 2016 involved 83 premenopausal women with polycystic ovary syndrome (PCOS) and 58 controls to investigate the predictivity of the Fatty Liver Index (FLI) for non-alcoholic fatty liver disease (NAFLD) in lean and overweight/obese females with PCOS. The results showed that γ-glutamyl transferase levels were significantly higher in females with PCOS than in the controls (p = 0.001), and FLI was significantly higher in females with NAFLD compared to those without NAFLD (47.1 ± 33.6 vs. 16.9 ± 21.6; p = 0.001). Body Mass Index had the strongest relationship with FLI in the PCOS group (p < 0.05, r = 0.908). Lean females with PCOS had a significantly higher rate of NAFLD (27.5% vs. 8.8%; p = 0.041) than lean controls. The study concluded that an FLI < 30 was not sufficient to rule out NAFLD in lean PCOS patients.
View this study on ajol.info →
Cited in this study
research Global Adiposity and Thickness of Intraperitoneal and Mesenteric Adipose Tissue Depots Are Increased in Women With Polycystic Ovary Syndrome (PCOS)
Women with PCOS have more body fat and thicker fat layers in certain abdominal areas than women without PCOS.
research Prevalence of hepatic steatosis in women with polycystic ovary syndrome
Women with PCOS are more likely to have fatty liver disease, especially if they have metabolic problems.
research Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)
The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.